Evidence map›Paper›PMID 40791474›Full record

ArticlebioRxiv : the preprint server for biology2025

Controlling treatment toxicity in ovarian cancer to prime the patient for tumor extinction therapy.

Kit Gallagher, Rachel S Sousa, Chandler Gatenbee, Ryan Schenck, Peng Chen, Timon Citak, Sydney Leither, Lucia Mazzacurati, Agata Xella, Zoe Zhou and 4 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kit GallagherWolfson Centre for Mathematical Biology, Mathematical Institute, Oxford, UK.ORCID 0000-0003-1401-115X
Rachel S SousaCenter for Complex Biological Systems, University of California Irvine, Irvine, California, USA.ORCID 0009-0003-0896-6926
Chandler GatenbeeDepartment of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.ORCID 0000-0002-9730-5964
Ryan SchenckStanford Cancer Institute, Stanford University, California, USA.ORCID 0000-0002-0294-0106
Peng ChenDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Ohio, USA.ORCID 0009-0005-4820-914X
Timon CitakMax-Planck-Zentrum für Physik und Medizin & Max Planck Institute for the Science of Light, Erlangen, Germany.ORCID 0009-0008-3231-5476
Sydney LeitherDepartment of Computer Science and Engineering, Michigan State University, Michigan, USA.ORCID 0009-0002-9636-1910
Lucia MazzacuratiDepartment of Gynecologic Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.ORCID 0000-0002-8336-8032
Agata XellaDepartment of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.ORCID 0000-0003-0353-2566
Zoe ZhouDepartment of Gynecologic Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
Dawn LemanneOregon Integrative Oncology, Ashland, Oregon, USA.ORCID 0000-0003-3391-7694
Paulo RodriguezDepartment of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.ORCID 0000-0001-7480-6566
Erin GeorgeDepartment of Gynecologic Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
Maximilian A R StroblDepartment of Translational Hematology and Oncology Research, Cleveland Clinic, Ohio, USA.ORCID 0000-0003-4484-8823

Funding

"Research Supplement to Promote Diversity in Health-Related Research", as part of Moffitt PS-OC, "Cancer as a Complex adaptive System"U54CA193489 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI ANDERSON, ALEXANDER ROBERTSON ALLAN, GATENBY, ROBERT A · 2015 to 2020
$12.5M
NCI NIH HHS U54 CA193489
6 · The paper itself

Abstract

High-grade serous ovarian cancer (HGSOC) remains a major clinical challenge. In particular among those patients with homologous recombination (HR)-proficient tumors (>50%), most eventually succumb to their disease due to high recurrence rates, acquired resistance, and cumulative toxicity. This report summarizes work from the 12

Indexed as

Extinction TherapyMathematical ModelingOvarian CancerToxicity Management

Identifiers

PMID40791474
PMCPMC12338546

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.